{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:09:11Z","timestamp":1791173351030,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2648,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,6]]},"abstract":"\n \n \n The role of the humoral immune response in the natural course of hepatitis C virus (HCV) infection is widely debated. Most chronically infected patients have immunoglobulin G (IgG) antibodies capable of neutralizing HCV pseudoparticles (HCVpp)<\/jats:bold>\n in vitro<\/jats:bold>\n . It is, however, not clear whether these IgG can prevent a<\/jats:bold>\n de novo<\/jats:bold>\n HCV infection<\/jats:bold>\n in vivo<\/jats:bold>\n and contribute to the control of viremia in infected individuals. We addressed this question with homologous<\/jats:bold>\n in vivo<\/jats:bold>\n protection studies in human liver\u2013urokinase-type plasminogen activator (uPA)+\/+ severe combined immune deficient (SCID) mice. Chimeric mice were loaded with chronic phase polyclonal IgG and challenged 3 days later with a 100% infectious dose of the acute phase H77C virus, both originating from patient H. Passive immunization induced sterilizing immunity in five of eight challenged animals. In the three nonprotected animals, the HCV infection was attenuated, as evidenced by altered viral kinetics in comparison with five control IgG-treated animals. Plasma samples obtained from the mice at viral challenge neutralized H77C-HCVpp at dilutions as high as 1\/400. Infection was completely prevented when, before administration to na\u00efve chimeric mice, the inoculum was pre-incubated<\/jats:bold>\n in vitro<\/jats:bold>\n at an IgG concentration normally observed in humans.<\/jats:bold>\n Conclusion:<\/jats:bold>\n Polyclonal IgG from a patient with a long-standing HCV infection not only displays neutralizing activity<\/jats:bold>\n in vitro<\/jats:bold>\n using the HCVpp system, but also conveys sterilizing immunity toward the ancestral HCV strain<\/jats:bold>\n in vivo<\/jats:bold>\n , using the human liver\u2013chimeric mouse model. Both experimental systems will be useful tools to identify neutralizing antibodies for future clinical use.<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/hep.22244","type":"journal-article","created":{"date-parts":[[2008,2,7]],"date-time":"2008-02-07T10:26:44Z","timestamp":1202380004000},"page":"1846-1855","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":138,"title":["Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver\u2013chimeric mice from infection with a homologous hepatitis C virus strain"],"prefix":"10.1097","volume":"47","author":[{"given":"Thomas","family":"Vanwolleghem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desombere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20241201","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/lt.20405","article-title":"A randomized, openlabel study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients.","volume":"11","author":"Davis","year":"2005","journal-title":"Liver Transpl"},{"key":"R2-11-20241201","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0168-8278(02)80095-2","article-title":"AntiHCV human immunoglobulins for the prevention of graft infection in HCVrelated liver transplantation, a pilot study.","volume":"36","author":"Willems","year":"2002","journal-title":"J Hepatol"},{"key":"R3-11-20241201","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/infdis\/173.4.822","article-title":"Effect of immune globulin on the prevention of experimental hepatitis C virus infection.","volume":"173","author":"Krawczynski","year":"1996","journal-title":"J Infect Dis"},{"key":"R4-11-20241201","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/lt.20876","article-title":"Monoclonal antibody HCVAbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study.","volume":"12","author":"Schiano","year":"2006","journal-title":"Liver Transpl"},{"key":"R5-11-20241201","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1073\/pnas.0402458101","article-title":"Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from antiHCVpositive plasma.","volume":"101","author":"Yu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-11-20241201","doi-asserted-by":"crossref","first-page":"10149","DOI":"10.1073\/pnas.0403519101","article-title":"Neutralizing antibody response during acute and chronic hepatitis C virus infection.","volume":"101","author":"Logvinoff","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-11-20241201","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1073\/pnas.0501275102","article-title":"Evidence for crossgenotype neutralization of hepatitis C virus pseudoparticles and enhancement of infectivity by apolipoprotein C1.","volume":"102","author":"Meunier","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R8-11-20241201","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1073\/pnas.91.16.7792","article-title":"Prevention of hepatitis C virus infection in chimpanzees after antibodymediated in vitro neutralization.","volume":"91","author":"Farci","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-11-20241201","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","article-title":"Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.","volume":"79","author":"Lavillette","year":"2005","journal-title":"J Virol"},{"key":"R10-11-20241201","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virusneutralizing antibodies and viral clearance in a singlesource outbreak of hepatitis C.","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-11-20241201","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.78.13.6875-6882.2004","article-title":"Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins.","volume":"78","author":"Flint","year":"2004","journal-title":"J Virol"},{"key":"R12-11-20241201","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes.","volume":"197","author":"Bartosch","year":"2003","journal-title":"J Exp Med"},{"key":"R13-11-20241201","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/90968","article-title":"Hepatitis C virus replication in mice with chimeric human livers.","volume":"7","author":"Mercer","year":"2001","journal-title":"Nat Med"},{"key":"R14-11-20241201","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.20657","article-title":"Morphological and biochemical characterization of a human liver in a uPASCID mouse chimera.","volume":"41","author":"Meuleman","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R15-11-20241201","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1073\/pnas.0511218103","article-title":"Cell culturegrown hepatitis C virus is infectious in vivo and can be recultured in vitro.","volume":"103","author":"Lindenbach","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-11-20241201","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/infdis\/144.6.588","article-title":"NonA, nonB hepatitis in chimpanzees and marmosets.","volume":"144","author":"Feinstone","year":"1981","journal-title":"J Infect Dis"},{"key":"R17-11-20241201","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.antiviral.2006.10.013","article-title":"Inhibition of replication of primary HIV1 isolates in huPBLNODScid mice by antibodies from HIV1 infected patients.","volume":"75","author":"Steyaert","year":"2007","journal-title":"Antiviral Res"},{"key":"R18-11-20241201","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0006-291X(03)01388-3","article-title":"A simple and rapid method to determine the zygosity of uPAtransgenic SCID mice.","volume":"308","author":"Meuleman","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"R19-11-20241201","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1365-2249.2000.01099.x","article-title":"Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice.","volume":"119","author":"Tournoy","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"R20-11-20241201","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1073\/pnas.94.16.8738","article-title":"Transcripts from a single fulllength cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee.","volume":"94","author":"Yanagi","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-11-20241201","doi-asserted-by":"crossref","first-page":"7208","DOI":"10.1128\/JVI.01774-06","article-title":"In vivo study of the HCTN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHCTN) are infectious in chimpanzees but not in Huh7.5 cells.","volume":"81","author":"Sakai","year":"2007","journal-title":"J Virol"},{"key":"R22-11-20241201","doi-asserted-by":"crossref","first-page":"14199","DOI":"10.1073\/pnas.2335981100","article-title":"In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.","volume":"100","author":"Bartosch","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-11-20241201","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2006.12.008","article-title":"Hepatitis C virus continuously escapes from neutralizing antibody and Tcell responses during chronic infection in vivo.","volume":"132","author":"von Hahn","year":"2007","journal-title":"Gastroenterology"},{"key":"R24-11-20241201","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/jhep.2000.9877","article-title":"Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.","volume":"32","author":"Forns","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R25-11-20241201","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/1097-0142(19940201)73:3+<794::AID-CNCR2820731308>3.0.CO;2-A","article-title":"The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G.","volume":"73","author":"Zuckier","year":"1994","journal-title":"Cancer"},{"key":"R26-11-20241201","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferonalpha therapy.","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"R27-11-20241201","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection.","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"R28-11-20241201","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nature04078","article-title":"Evasion of intracellular host defence by hepatitis C virus.","volume":"436","author":"Gale","year":"2005","journal-title":"Nature"},{"key":"R29-11-20241201","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1371\/journal.ppat.0020059","article-title":"Hostspecific response to HCV infection in the chimeric SCIDbeigeAlbuPA mouse model: role of the innate antiviral immune response.","volume":"2","author":"Walters","year":"2006","journal-title":"PLoS Pathog"},{"key":"R30-11-20241201","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nri891","article-title":"Antibodies, viruses and vaccines.","volume":"2","author":"Burton","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"R31-11-20241201","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1073\/pnas.0700760104","article-title":"Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very lowdensity lipoproteins.","volume":"104","author":"Huang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22244","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01515467-200806000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:52:30Z","timestamp":1786035150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01515467-200806000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22244","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}